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interferon Control of the Sterol 
Metabolic Network: Bidirectional 
Molecular Circuitry-Mediating Host 
Protection
Kevin A. Robertson* and Peter Ghazal*
Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, UK
The sterol metabolic network is emerging center stage in inflammation and immunity. 
Historically, observational clinical studies show that hypocholesterolemia is a common 
side effect of interferon (IFN) treatment. More recently, comprehensive systems-wide 
investigations of the macrophage IFN response reveal a direct molecular link between 
cholesterol metabolism and infection. Upon infection, flux through the sterol metabolic 
network is acutely moderated by the IFN response at multiple regulatory levels. The 
precise mechanisms by which IFN regulates the mevalonate-sterol pathway—the spine 
of the network—are beginning to be unraveled. In this review, we discuss our current 
understanding of the multifactorial mechanisms by which IFN regulates the sterol path-
way. We also consider bidirectional communications resulting in sterol metabolism regu-
lation of immunity. Finally, we deliberate on how this fundamental interaction functions as 
an integral element of host protective responses to infection and harmful inflammation.
Keywords: cholesterol, sterol, interferon, metabolism, miRNA, oxysterol, 25-hydroxycholesterol, miR-342-5p
iNTRODUCTiON
Immunity depends on and employs metabolic pathways for its function. Our knowledge of the 
molecular and functional mechanisms for this coupling has grown dramatically in recent years and 
it is now accepted that a remodeling of glycololytic, lipid biosynthetic, and associated homeostatic 
molecular “circuitry” is an integral component of innate and adaptive immune responses (1–3). 
In particular, multiple immune-mediated mechanisms for the transcriptional, posttranscriptional, 
translational, and posttranslational regulation of lipid biosynthesis, storage, influx, and efflux in 
immune cells have been described (4–7). Broadly, with some notable exceptions, these mechanisms 
have been defined in vitro in specific cell types (e.g., macrophages) and their general significance and 
relative importance in vivo have yet to be fully characterized.
Abbreviations: 7α,25-HC, 7α,25-dihydroxycholesterol; 25-HC, 25-hydroxycholesterol; CH25H, cholesterol 25-hydroxylase; 
EBI2, EBV-induced G-protein coupled receptor 2 (also known as GPR183); HCV, hepatitis C virus; HDL, high-density lipopro-
tein; HIV-1, human immunodeficiency virus 1; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HSV1, herpes simplex 
virus type 1; IAV, influenza A virus; IFN, interferon; IRF, interferon regulatory factor; LDL, low-density lipoprotein; LXR, liver 
X receptor; MCMV, murine cytomegalovirus; MHV-68, murine gammaherpesvirus 68; SREBP2, sterol regulatory-binding 
protein 2; SREBF2, sterol regulatory-binding transcription factor 2; TLR, toll-like receptor; VSV, vesicular stomatitis virus; 
VZV, varicella zoster virus; WNV, West Nile virus.
FigURe 1 | Heat map showing 1,048 genes significantly increased or decreased in expression after interferon (iFN) simulation of macrophages. Bone 
marrow-derived macrophages were mock treated or treated with 10 U/ml IFN and then sampled at 30-min intervals for a period of 12 h. Total RNA was then labeled 
and hybridized to Mouse Agilent V2 (G4121A) microarrays. Gene expression is shown as a pseudo-color—blue, decrease; red, increase. Explorative and statistical 
analyses were undertaken as previously described (4). Data are available for download from the NCBI gene expression omnibus (https://www.ncbi.nlm.nih.gov/geo/) 
(series GSE42504).
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Immediately after infection, the ligation of cellular pattern-
recognition receptors by, for example, dsRNA leads to an 
induction of NFkB, ATF2/c-jun, and interferon regulatory factor 
3 (IRF3), a rapid upregulation of IFNα/β gene expression and 
secretion of type I IFNs by cells. The autocrine/paracrine binding 
of IFNα/β or IFN-γ (from activated NK and T cells) to type I or 
type II IFN receptors, respectively, leads to the activation of JAK/
STAT signaling pathways and rapid alterations in the abundance 
of hundreds of transcripts in the cell. These IFN-stimulated 
changes reflect an acute re-programing of the cell to resist infec-
tion and limit cellular damage. Figure 1 shows a high-resolution 
temporal (every 30 min for the first 12 h) analysis of genome-wide 
alterations in gene expression upon IFN-γ activation of bone 
marrow-derived macrophages. Importantly, alongside many 
IFN-stimulated genes, this data reveal an equivalent number of 
transcripts are significantly suppressed by IFN.
While interferon (IFN)-stimulated genes (ISG) such as 
NOS2, OAS2, MX2, and IFITM3 have intensively investigated 
antiviral or antibacterial effects, IFN downregulated transcripts 
have received relatively little attention (8–11). Notably, a statisti-
cal over-representation analysis of the IFN suppressed genes 
presented in Figure  1 identified the sterol metabolic network 
as a significantly over-represented component of this dataset. 
Importantly, consequent mechanistic studies demonstrated that a 
suppression of sterol biosynthesis is an integral component of the 
innate immune response to infection (4). This work raised several 
significant questions about the coupling of sterol metabolism to 
immunity. In particular, what are the molecular mechanisms by 
which IFN mediates a downregulation of the sterol biosynthesis 
pathway and how does the suppression of sterol biosynthesis 
benefit the infected host? Recent studies are beginning to answer 
some of these questions.
Here, we first discuss early clinical work showing iatrogenic 
effects of IFN on sterol metabolism. Next, with an emphasis 
on molecular oxysterol and miRNA-mediated mechanisms, we 
consider what is known about how IFN regulates sterol metabo-
lism. Overall, we advance the notion that the mevalonate–sterol 
pathway is an effector arm of immunity and highlight how this 
response helps the host limit excessive inflammation and resist 
infection.
HYPOCHOLeSTeROLeMiC eFFeCTS OF 
iFN TReATMeNT iN HUMANS
Although interest in IFN-mediated regulation of the sterol 
pathway has increased dramatically in recent years, IFN-induced 
alterations in cholesterol in humans have been reported for 
several decades (Table 1). In 1979, Baillie and Orr reported that 
acute viral infections are regularly associated with reductions in 
TABLe 1 | Representative clinical studies reporting decreases in cholesterol following treatment with type 1 or 2 iFN.
iFN type Year Treatment Disease context Observation Reference
Partly purified human 
leukocyte IFN
1980 1× healthy male volunteer: 10× daily 
SC injections of 3 × 106 IU. Two further 
volunteers: 1× SC of 3 × 106 IU, then 
3 × 1.5 × 106 IU on consecutive days
Healthy volunteer Drop in high-density lipoprotein (HDL) 
cholesterol in all volunteers 7 days after 
treatment
(13)
Human leukocyte IFN 1981 3 × 106 IU IFN IM daily for 1 week. 
6 × healthy male
Healthy volunteer Total and HDL plasma cholesterol 
decreased in all 6 subjects
(17)
Human IFN-α prepared from 
buffy coat leukocytes
1984 Daily IM injection of 3 × 106–9 × 106 U of (A) 
over 28–57 days
Cancer Significant decrease in HDL and total 
cholesterol
(18)
rIFN-αA  
(Hoffman–LaRoche Inc., 
Nutly, NJ, USA)
Daily IM injection of 3 × 106–5.4 × 107 U of 
(B) for 15 days
rIFN-βser  
(modified rIFN-β: Ser17 
substituted for cysteine)
1985 Escalating dose regime: IM and IV injection 
from 1 × 106 to 4 × 108 U, twice weekly
Cancer Decrease in serum cholesterol (19)
rIFN-α2 1986 3 × 107 U/m2 IV for 5 days consecutively 
every 3 weeks
Cancer Significant decrease in plasma 
cholesterol. Effect specific to low-density 
lipoprotein (LDL) and HDL. VLDL or 
triglycerides unchanged
(20)
rIFN-βser 1987 Patients randomly assigned to 1 of 2 
dose regimens. 4.5 × 106 U (3 males and 
7 females) or 9 × 107 U (8 males and 3 
females) of IFN-βser IV daily in a double blind 
manner for 10 days followed by 11 days off
Cancer Significant dose-dependent decrease in 
mean plasma total cholesterol and LDL 
concentrations (24–36 h after initiation 
of treatment). Approx. 25% reduction in 
plasma cholesterol concentration after 
10 days of treatment
(14)
IFN-α-n1 (Wellferon—highly 
purified combination of 
natural human IFNα from 
lymphoblastoid cells)
1988 9× men received IM treatment Refractory 
condylomata 
acuminata
All patients had significant decrease in 
HDL cholesterol levels. Total cholesterol 
decreased—change not significant
(21)
rIFN-βser 1990 Randomized, double-blind trial of two doses 
of IFN-βser (4.5 × 106 and 9 × 107 U). IV 
injections daily for 10 days with 11 days rest 
before treatment reinitiated
Cancer Statistically significant change in 
cholesterol
(15)
rIFN-γ 1990 29 patients treated IV at doses escalating 
from 2 × 105 to 108 IU/m2 in 9 successive 
steps (at least 3 patients/step). Injections of 
rIFN gamma were repeated every 72 h for 
15 days
Cancer Hypocholesterolemia observed in 18 
patients
(22)
rIFN-βser 1992 4.5 × 106 U daily IV for 5 weeks to normal 
and hypercholesteremic patients
Hypercholesteremia Significant 15% reduction of 
total cholesterol in normal and 
hypercholesterolemic subjects. IFN 
induced significant reductions in LDL 
cholesterol of 25% in normal subjects and 
of 40% in hypercholesterolemic subjects. 
Significant decreases in LDL apoB 
observed only in the normal group
(16)
rIFN-α2b 1995 44 patients were treated with human 
recombinant interferon (IFN)-alpha 
2b (3 × 106 U 3× per week for up to 
12 months). 8 control patients
Hepatitis C virus 
(HCV)
Blood lipids evaluated after 3, 30, and 
90 days of treatment. HDL, cholesterol, 
apolipoprotein A-I, and HDL3 decreased 
within 4 weeks of starting IFN treatment
(23)
rIFN-α2a 1997 39 patients: recombinant IFN alpha-2a 
(9 × 106 U/day) administered IM for 2 weeks, 
and then 3× a week for 6 months
HCV Serum cholesterol concentration 
significantly decreased 1 week after start 
of IFN administration. 67% of reduction 
attributable to HDL-cholesterol
(24)
(Continued)
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iFN type Year Treatment Disease context Observation Reference
rIFN-α2b (Intron A,  
Schering–Plough, Kenilworth, 
NJ, USA)
1998 36 patients received therapy with 
recombinant IFN-α2b for 6 months; 34 
patients received 5 × 106 U and 2 patients 
6 × 106 U, 3× a week
HCV Reduction in HDL-cholesterol and apoA1 
levels. Total, LDL, and lipoprotein(a) levels 
unchanged during treatment
(25)
rIFN-β (Frone, Serono, 
Madrid, Spain)
2000 IFN-β SC (6 × 106 U) 3× a week for 
6 months
HCV Cholesterol concentration decreased 
slightly in HDL subfractions
(26)
rIFNβ-1a (Avonex; Biogen 
Idec, Inc., Cambridge,  
MA, USA)
2004 95 patients: 6 × 106 U/week IM and SC 
IFNβ1a (Avonex)
92 patients: 8 × 106 U IFNβ1b every other 
day SC
41 patients: 22 µg 3× SC/week. IFNβ1a 
(Rebif)
25 patients: 3× SC/week 4 µg IFNβ1a (Rebif)
MS Highly significant sustained decrease 
(−8%) in mean cholesterol level in plasma 
of IFN-treated MS patients
(27)
rIFNβ1b (Betaferon—cys17 
replaced by ser17,  
lacks met1 and carbohydrate 
moieties—Schering,  
Berlin, Germany)
rIFNβ1a  
(Rebif, Ares-Serono,  
Geneva Switzerland)
rIFNβ-1a (Avonex; Biogen 
Idec, Inc., Cambridge,  
MA, USA)
2006 255 patients were included in the study MS Decrease in blood cholesterol (28)
Peg-rIFN 2016 520 patients treated with pegIFN or 
combination of IFN-free direct acting 
antivirals (DAA)
HCV IFN-based therapy decreased total 
circulating cholesterol, while IFN-free DAA 
increased cholesterol levels
(29)
TABLe 1 | Continued
4
Robertson and Ghazal How Does Interferon Regulate Cholesterol?
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 634
systemic cholesterol in patients (12). Subsequently, Cantell et al. 
(13) showed that the administration of partly purified human 
leukocyte IFN to volunteers led to a 20% drop in high-density 
lipoprotein (HDL), a transient declining trend in total cholesterol 
and put forward the first proposal that viral infections elicit a drop 
in cholesterol via the induction of IFN (13). Table 1 presents a 
chronological summary of wide-ranging studies in which natural 
and recombinant type I and type II IFNs have been administered 
to volunteers or patients with cancer, multiple sclerosis, human 
papilloma, or hepatitis C virus (HCV) infections. In all studies, 
despite differences in the preparation of IFN used, a drop in 
circulating total cholesterol and/or HDL was observed. Arguably, 
the strongest clinical evidence comes from prospective double 
blind studies such as those reported by Rosenzweig et  al. (14) 
and Borden et al. (15). The former utilized a double blind analysis 
to demonstrate a dose-dependent effect of IFN administration on 
plasma cholesterol (14). The latter employed a prospective double 
blind placebo-controlled analysis of IFN treatment in renal car-
cinoma patients, demonstrating a significant decrease in mean 
plasma total cholesterol (15). It is worth noting that Rosenzweig 
et al. (14) also showed that the effects of IFN were not permanent 
and that after cessation of treatment circulating cholesterol levels 
returned to normal in patients (14). In subsequent metabolic 
tracer experiments, the primary effect of IFN was shown to occur 
via a modulation of cholesterol synthesis (16).
In summary, the induction of hypocholesteremia by IFN has 
been recorded clinically for many years via an analysis of total 
cholesterol, HDL, or LDL in the circulation. Despite this recogni-
tion, physiological roles related to human health and underpin-
ning this observation have not been further investigated.
THe MevALONATe-STeROL PATHwAY iS 
AN iNTRiNSiC COMPONeNT OF THe iFN 
ReSPONSe TO iNFeCTiON
Alongside, clinical studies demonstrating exogenously adminis-
tered IFN can regulate sterol metabolism, a number of groups 
have also associated cholesterol regulation with IFN responses in 
experimental animal studies. In 1984, Kuo et al. showed that IFN-
inducing agents significantly reduced cholesterol deposits in the 
aortas of rabbits fed a pro-atherogenic diet (30). Further, in 1987, 
Pereira et al. showed that a hypercholesteremic diet resulted in an 
increased susceptibility to murine hepatitis virus in A/J mice—a 
result in part due to a decreased response to IFN and reduced 
antiviral state (31). A key question in this context is: what benefit 
to the host is conferred by the IFN regulation of sterol metabolism? 
While studies prior to 2011 showed that toll-like receptor 3 
(TLR3) or TLR4 ligation results in an IFN-independent inhibi-
tion of cholesterol efflux from the cell, little was known at this 
point about how IFN signaling directly influences cholesterol 
homeostasis and the physiological purpose this could serve (32). 
In 2011, Blanc et al. demonstrated that viral infection or treat-
ment of macrophages with type I or II IFN results in a coordinate, 
negative regulation of the entire sterol biosynthesis pathway and 
that inflammatory cytokines such as TNF, IL-6, and IL1β are inca-
pable of eliciting a similar effect. This study further showed that 
the regulation of the sterol pathway by IFN is, at least partly, due 
to a reduction in SREBF2 transcription and SREBP2 abundance 
and that this event is an integral component of the cell-intrinsic 
antiviral response (4). Notably, a recent study highlighted the 
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interdependent reciprocal nature of the molecular circuitry cou-
pling IFN and sterol metabolism. In 2015, York et al. described 
a STING-dependent recognition of decreased flux through the 
sterol biosynthetic pathway leading to positive feedback that 
enhances the type I IFN response and antiviral gene expression in 
the context of gammaherpesvirus infection (33). The implications 
of this data are discussed later in this review.
FUNCTiONAL ROLeS FOR THe 
MevALONATe-STeROL PATHwAY  
iN gOveRNiNg ADAPTive iMMUNe 
ReSPONSeS
Beyond the intracellular and/or cell-intrinsic environment, 
IFN-mediated regulation of sterol metabolism has the potential 
to influence many aspects of immunity. The functions that 
the sterol metabolic network plays in a wide range of adaptive 
immune responses have recently been reviewed (3). These 
include: an absolute requirement for SREBP2 functionality 
during activated T lymphocyte clonal expansion, a requirement 
for flux through the sterol biosynthesis pathway during the 
activation of T regulatory cell function, the observation that a 
hypercholesteremia can alter the balance of the Treg and T effec-
tor cells, and the induction of lymphocyte hyper-proliferation 
due to impaired cholesterol efflux (34–38). Cholesterol is also 
indispensable in the formation of lipid raft microdomains— 
crucial to the assembly of cell surface signaling molecules such 
as the T and B cell receptors—and has recently been identified as 
a critical allosteric regulator of TCR priming (39, 40). Notably, 
cholesterol is not the only output of the sterol biosynthesis path-
way on which cells depend. For example, prenylation of the Ras 
family of GTPases by the side branch of the mevalonate pathway 
is integral to the control of T cell differentiation, proliferation, 
and cytokine production [reviewed in Ref. (41)]. Further, sterol 
pathway intermediates have also been identified as endogenous 
ligands for the transcription factor RORγt. RORγt is required 
for the differentiation of naïve CD4+ T lymphocytes into TH17 
cells, a subset of lymphocytes associated with a range of autoim-
mune diseases and mediating protective immune responses to 
pathogens such as Klebsiella pneumoniae, Bordetella pertussis, 
Mycobacterium tuberculosis, and Candida albicans (42–45). 
Santori and colleagues identified sterol pathway intermediates 
generated downstream of lanosterol and above zymosterol as 
natural ligands of RORγt, while Hu et  al. suggested that des-
mosterol (downstream of zymosterol and recently shown to be 
negatively regulated by IFN) is a potential endogenous ligand 
for this transcription factor (7, 46). Through the utilization 
of chemical library screening studies, the oxysterol 7β,26-
dihydroxycholesterol (synthesized from 7β-hydroxycholesterol, 
a metabolite immediately downstream of cholesterol) has also 
been identified as a potent ligand of RORγt (47). In summary, 
the sterol metabolic network is increasingly viewed as integral 
to the activation and differentiation of T lymphocytes. More 
work, however, is required to better understand the precise 
mechanisms by which the network and/or specific metabolites 
function in these processes.
In B lymphocytes, IFN regulation of sterol metabolism may 
lead to alterations in lipid raft cholesterol composition and, in 
doing so, affect antigen processing/presentation (48) and B-cell 
receptor signaling (48–50). Notably, significant roles for the 
inflammatory sterol pathway product 25-hydroxycholesterol and 
7α,25-dihydroxycholesterol in class-switching and the chemoat-
traction of B lymphocytes to germinal centers have recently been 
described and these will be discussed in detail later.
BeNeFiTS OF iFN-MeDiATeD STeROL 
RegULATiON DURiNg iNFeCTiON
An IFN-mediated suppression of sterol metabolism has the 
potential to directly curtail the replication of microorganisms 
in the host. Pathogens with a dependency on the host sterol 
metabolic network include HCV, human immunodeficiency 
virus (HIV), Ebola, the Herpesvirus family [HCMV, murine 
cytomegalovirus (MCMV), herpes simplex virus type (HSV1) 
MHV-68, and varicella zoster virus (VZV)], Influenza A virus 
(IAV), Listeria monocytogenes, and M. tuberculosis (51–57). 
Importantly, the requirements of these organisms on the system 
vary dramatically. For example, lipid rafts play an integral role 
in the entry, assembly, and release of a wide range of unrelated 
viruses (enveloped and non-enveloped) such as HIV1, Ebola, 
Influenza A, and Echovirus 1 [reviewed here in Ref. (58)]. In 
contrast, HCMV uses cholesterol for envelopment and limiting 
the availability of intracellular cholesterol levels has been shown 
to restrict infectivity of this virus (59). The replication of several 
viruses also requires prenylation of host and/or virus proteins. 
For example, hepatitis D virus requires prenylation of its large 
delta antigen for optimal virion morphogenesis, HCV requires 
the geranylgeranylated host protein FBL2 for replication, and 
respiratory syncytial virus (RSV) F glycoprotein binds to the pre-
nylated host protein RHOA enabling membrane fusion (60–62). 
In the context of bacterial infection, Listeriolysin O, the major 
virulence factor of the intracellular bacteria L. monocytogenes, is 
a cholesterol-dependent cytolysin (CDC) responsible for a wide 
array of functions including disruption of the internalization 
vacuole (54). Further, M. tuberculosis has cholesterol uptake 
machinery, an enzyme system capable of catabolizing sterols for 
growth and potentially utilizes sterols as a carbon and energy 
source (55, 63).
It is perhaps unsurprising, given the essential role sterol 
metabolism plays in their replication, that examples are appear-
ing of pathogens subverting or co-opting the regulation of this 
system for their own benefit. In 2007, Mackenzie et al. showed 
that a West Nile virus (WNV) infection of Vero cells induced 
an upregulation of cholesterol biosynthesis and redistribution 
of cholesterol resulting in defective IFN-stimulated JAK/STAT 
signaling. This result was attributed to a disrupted recruitment 
and activation of the type 1 IFN receptor and IFN signaling pro-
teins and emphasizes the tight integration of IFN and cholesterol 
regulation in the cell (64).
In summary, evidence increasingly reveals an intimate molec-
ular coupling between IFN signaling and the sterol metabolic 
network. This underscores the importance of immune-mediated 
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regulation of sterol metabolism as an integral component of the 
host response to infection.
CeLLULAR MeCHANiSMS FOR iFN 
RegULATiON OF THe STeROL 
MeTABOLiC NeTwORK
A prototypic outcome of IFN signaling in the cell is the transcrip-
tional activation or suppression of hundreds of genes. Over the 
past 5 years, significant progress in characterizing which of these 
genes contribute to regulation of cholesterol in the cell has been 
made. In this regard, oxysterol and miRNA-mediated mecha-
nisms have risen to prominence and, in the following sections, 
we will review what is known about the functions of IFN-elicited 
CH25H/25-HC and miRNA-mediated sterol regulation. We will 
then conclude by considering mechanisms of cholesterol regula-
tion by the “conventional” ISG Viperin and the IFITM protein 
family.
iFN-iNDUCeD 
25-HYDROXYCHOLeSTeROL iN 
iNFeCTiON AND iMMUNiTY
While cholesterol is a critical component of cell membranes 
and a precursor of bile acids and steroid hormones, at high 
concentrations, it may be toxic to the cell. Intracellular choles-
terol homeostasis is, therefore, stringently controlled by tightly 
coupled regulatory mechanisms including influx and efflux, 
esterification, and storage and biosynthesis (65). Oxysterols are 
oxygenated forms of cholesterol formed directly from cholesterol 
(or oxysterols derived from cholesterol) by enzymatic and non-
enzymatic mechanisms (55). Functionally, oxysterols such as 
22(R)-hydroxycholesterol and 24(S)-hydroxycholesterol potently 
bind ligand-activated transcription factors liver X receptor 
(LXR)-α and/or LXR-β and induce the upregulation of cholesterol 
homeostasis-related proteins such as ABCA1—responsible for 
cholesterol efflux from the cell (66, 67). Notably, however, despite 
its identification over 50 years ago and an early demonstration of 
potent sterol biosynthesis regulatory feedback functionality, until 
recently, physiological roles for 25-hydroxycholesterol (25-HC) 
have proven elusive (68, 69).
25-HC binds the INSIG protein in the ER and, in doing 
so, prevents SREBP2 transport to the golgi/nucleus and 
cholesterol biosynthesis [reviewed in Ref. (70)]. It is not, 
however, a strong activator of the LXRs nor does it play a 
significant role in systemic cholesterol homeostasis in  vivo 
(71). In 2009, independent studies showed that CH25H, the 
enzyme responsible for 25-HC synthesis, is transcriptionally 
upregulated in macrophages following treatment with a TLR 
agonist (72, 73). Park and Scott (74) then showed that type 
I IFNs are also capable of upregulating CH25H (74). While 
this evidence supported the notion that 25-HC may play 
a role in immunity, in fact, studies had been emerging for 
decades implicating 25-HC in the immune response to infec-
tion. In  1986, Kournikakis et  al. demonstrated that 25-HC 
can suppress antibody-dependent cell cytotoxicity, and in 
1998, Moog et  al. showed 25-HC (but not cholesterol) can 
inhibit HIV in  vitro (75, 76). Over the next decade, several 
groups independently investigated the effects of 25-HC on 
HCV subgenomic replicon replication and found the oxysterol 
inhibited this process (77–80). Notably, the effects of 25-HC 
are not restricted to viruses, and in 2006, Howe and Heinzen 
described a partial inhibition of the bacteria Coxiella burnetii 
following treatment of Vero cells with this oxysterol (81).
BROAD ANTiviRAL FUNCTiONALiTY  
OF 25-HC
Interest in the regulation and functions of 25-HC (and its deriva-
tives) has increased dramatically in recent years [reviewed in 
Ref. (82)]. In 2012, Gold et al. demonstrated that ATF3 directly 
suppresses the transcription of CH25H and the production of 
25-HC. They further showed that a deletion of ATF3 in APOE−/− 
mice results in enhanced aortic 25-HC expression and foam cell 
development (83). In 2013, Blanc et al. showed that 25-HC is the 
only oxysterol synthesized (and secreted) in significant quantities 
by murine macrophages after IFN activation and demonstrated 
that the transcription of CH25H is directly regulated by IFN 
through the binding of STAT1 to its promoter. These studies also 
showed that physiological levels of 25-HC have a broad antiviral 
functionality mediated, in the case of cytomegalovirus (CMV), 
post-entry via regulation of the sterol biosynthesis pathway. Data 
presented by Blanc et al. supported an important role for the pre-
nylation side-branch of the sterol biosynthesis pathway, rather 
than cholesterol, in mediating antiviral effects against CMV (52). 
At the same time, Liu et  al. (84), using a molecular screening 
approach, also identified CH25H as an important IFN-stimulated 
gene and demonstrated a broad antiviral functionality for 25-HC 
(84). Contrary to the CMV-related work of Blanc et al., however, 
Liu et  al. found this effect was mediated via an inhibition of 
pathogen [vesicular stomatitis virus (VSV) and (HIV)] entry 
to the cell. The distinct modes of 25-HC action described likely 
reflect differences between the cell/virus systems examined. Liu 
et al. further showed that CH25H−/− mice are more susceptible to 
MHV-68 infection and the therapeutic administration of 25-HC 
to humanized mice suppressed HIV-induced T cell depletion 
(84). Together, these studies identified a significant new role for 
25-HC as an effector in the immune response to infection and, 
since 2013, several independent studies have described further 
roles for 25-HC in this context. In 2014, Roulin et al. showed that 
25-HC suppresses picornavirus infections by displacing choles-
terol binding to the oxysterol sterol-binding protein (OSBP1). 
In doing so, 25-HC disrupts a cholesterol-phosphatidylinositol 
4-phosphate counter-current essential for formation of the 
replication organelle at ER–Golgi membrane contact sites (85). 
Building on early studies investigating sterol pathway regulation, 
in 2015, Lu et  al. showed that, alongside its ability to inhibit 
SREBP2 migration to the nucleus, IFN-elicited 25-HC induces 
a rapid proteosomal degradation of HMGCR in macrophages 
(6, 86). Work has also shown that 25-HC can inhibit a wide range 
of unrelated enveloped and non-enveloped viruses including 
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poliovirus, Hepatitis B and C viruses, human papillomavirus 
(HPV-16), human rotavirus, encephalomyocarditis virus, and 
SFTS virus (87–92). Recent studies have also revealed more detail 
regarding the regulation of CH25H. Mboko et al. (93) showed 
that CH25H expression in mice is, at least partly, dependent on 
IRF1 and Xiang et  al. (94) demonstrated an IFN-independent 
induction of CH25H in hepatocytes in response to viral infection 
(93, 94). In this regard, evidence to-date suggests that CH25H 
gene expression is regulated in a cell-specific manner and it 
cannot be considered a prototypic ISG. While the majority of 
studies have broadly focused on the ability of 25-HC to suppress 
infection via regulation of lipid metabolism, data from Shibata 
et al. (5) suggest that it may also achieve this via a specific activa-
tion of the GCN2/eIF2α/ATF4 branch of the integrated stress 
response (ISR) (5).
Notably, recent studies describe direct interactions of both 
CH25H and 25-HC with gene products of the microorganism. 
Chen et  al. (95) describe a direct interaction between CH25H 
and NS5A of HCV leading to an inhibition of NS5A dimerization 
and inhibition of HCV replication (95). More recently, Ren et al. 
(96) describe an INSIG homolog with predicted 25-HC-binding 
capacity in the bacterium Mycobacterium vanbaalenii (96). What 
physiological role this would play, however, remains unclear.
In summary, it is now accepted that 25-HC is an important 
component of the IFN-induced response to infection and a range 
of studies have identified divergent mechanisms for the inhibition 
of entry, replication, and exit from the cell.
25-HC AS AN iNFLAMMATORY MeDiATOR
Recent evidence has emerged supporting a role for 25-HC as a 
pro- and/or anti-inflammatory mediator. In 2010, it was demon-
strated that 25-HC has the capacity to suppress CCR7 expression 
and thus impair DC migration (97). Wang et  al. subsequently 
described a 25-HC-elicited RIG-I-dependent induction of IL-8 
and Raccosta et al. showed that 25-HC can bind CXCR2 (98, 99). 
In 2014, Data from Reboldi et al. showed that in macrophages, 
through its ability to antagonize SREBP, 25-HC can reduce 
IL-1β expression and inflammasome activation. They further 
demonstrated that CH25H−/− mice are more sensitive to septic 
shock and have an enhanced ability to suppress L. monocytogenes 
infection (100). In contrast, Gold et  al. (101) describe 25-HC 
as an amplifier of inflammation, showing a reduction in pro-
inflammatory gene expression in poly I:C treated CH25H−/− 
macrophages and decreased inflammatory pathology in the 
lungs of Influenza virus-infected mice (101). Further evidence 
of a pro-inflammatory role for 25-HC has very recently emerged 
from Jang et al. (102) who describe a role for the oxysterol as an 
endogenous signal for NLRP3/inflammasome activation during 
cerebral inflammation (102). At present, therefore, evidence 
would appear to support multiple roles for 25-HC in the regula-
tion of inflammation.
An important consideration in the analysis and interpretation 
of 25-HC-related data is the concentration of exogenous oxys-
terol utilized in vitro. Others, and ourselves, have demonstrated 
that nanomolar concentrations of 25-HC elicit profound effects 
in primary macrophages, e.g., Ref. (52, 100). In the literature, 
however, functional roles for 25-HC have been defined after 
treatment of cells with considerably higher concentrations (e.g., 
10–100µM)—for instance (99, 102). Caution should be exercised 
when interpreting data from experiments utilizing arguably 
supraphysiological concentrations of the oxysterol. In this regard, 
more work—in particular in  vivo—is required to characterize 
the specific concentrations, circumstances, locations, and times 
at which pro- or anti-inflammatory effects are observed during 
infection.
CH25H AND ACQUiReD iMMUNe 
ReSPONSeS
In 2009, Bauman et al. described a role for 25-HC in the direct 
repression of B cell proliferation and immunoglobulin class 
switching (72). Oxysterols are often subject to consecutive 
modifications in order that a functional effector molecule can 
be synthesized, and in 2011, two groups identified 7α,25-HC—
generated via the hydroxylation of 25-HC by CYP7B1—as a 
ligand for the receptor EBI2 (71, 82, 103, 104). While studies 
of 25-HC have broadly focused on its production and function 
in macrophages, 7α,25-HC is primarily synthesized in radiation 
resistant stromal cells (105). The 7α,25-HC receptor EBI2 is 
expressed throughout the immune system and, to-date, has been 
shown to play a critical role in B lymphocyte and dendritic cell 
biology. In B lymphocytes, EBI2 binding of 7α,25-HC, induces 
a series of temporally regulated migratory events. B cells first 
move to the outer follicles of lymphoid tissues, then migrate 
to the T cell margin, and finally move to interfollicular regions 
before EBI2 is downregulated and germinal centers form (82, 
106). Ultimately, binding of 7α,25-HC to EBI2 and subsequent 
B cell repositioning events are crucial to antibody responses 
and CH25H−/− mice have reduced IgG and IgM responses to 
T  cell-dependent antigens (107, 108). In dendritic cells, EBI2 
and 7α,25-HC are also crucial and determine cellular migration/
location and ability of these cells to support CD4 and B cells 
responses to blood borne antigens (82, 109).
Importantly, roles for 25-HC and downstream metabolites 
in the regulation of T lymphocyte responses are emerging. In 
2014, data from Chalmin et  al. suggested that 7α,25-HC may 
direct the migration of activated T cells into the CNS in a model 
of autoimmune encephalomyelitis. Further, a very recent study 
from Li et al. (110) has described a role for 25-HC in T helper 
cell development. Specifically, through an interaction with T 
lymphocyte EBI2, 7α,25-HC functions to orientate T cells at 
the interface of the follicle and the T cell zone. In doing so, it 
promotes TFH cell differentiation by facilitating interactions first 
between the lymphocytes and ICOSLHI CD25+ dendritic cells and 
subsequently between lymphocytes and B cells (110).
Evidence is rapidly accumulating that multiple complemen-
tary mechanisms are responsible for the molecular coupling of 
IFN to sterol metabolism. In this context, Singaravelu et al. (111) 
recently described an ability of 25-HC to induce the expres-
sion miR-185 and, in doing so, regulate host lipid metabolism 
pathways critical to HCV replication (111). This finding will be 
discussed in more detail later.
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HOw DOeS 25-HC SUPPReSS 
iNFeCTiON?
For almost four decades, a physiological role for 25-HC remained 
elusive, however, multiple lines of evidence now show that the 
direct induction of CH25H expression and 25-HC synthesis by 
IFN is a fundamentally important feature of immune responses to 
infection. A key unanswered question is: what are the mechanisms 
by which 25-HC can suppress infection?
Studies to-date have primarily utilized 25-HC as a research 
tool to study the functional role of cholesterol homeostasis and 
its effects on membrane composition, vesicular trafficking, and 
isoprenylation. The addition of exogenous side-chain oxysterols 
such as 25-HC to cells is known to elicit trafficking of cholesterol 
from the membrane to the ER—an event that may perturb mem-
brane architecture and the orientation and composition of, for 
example, lipid rafts (112). Via an interaction with OSBP1, 25-HC 
is also known to disrupt a cholesterol-phosphatidylinositol 
4-phosphate “counter-current” required for ER to golgi choles-
terol transport and Rhinovirus replication (85). In 2013, Liu et al. 
found 25-HC-inhibited membrane fusion and cellular infections 
by HIV, Ebola, and HCV (84). In contrast, Blanc et al. (52) found 
that 25-HC had a minimal effect on MCMV entry and, by utiliz-
ing a mathematical model, estimated that entry-related effects of 
this oxysterol account for only 10% of its overall antiviral activity 
for this virus. Data from Blanc et al. (52) support the view that 
25-HC primarily exerts its effects by limiting mevalonate–sterol 
biosynthesis pathway flux. In particular, flux associated with 
the isoprenoid branch is responsible for protein prenylation 
(52). Prenylation refers to the posttranslational modification 
of proteins by the covalent addition of farnesyl (C15) or gera-
nylgeranyl (C20) to conserved amino acid motifs and is key to 
protein–membrane interactions/intracellular localization of, for 
example, the Rab proteins. The Rab GTPase superfamily has more 
than 20 members playing essential roles in vesicle trafficking 
and protein localization in the cell. Prenylation is the key to this 
function as it allows attachment of the protein to the lipid bilayer. 
An ability to inhibit the prenylation and, therefore, the function 
of Rab GTPases may allow 25-HC to influence a wide range of 
pathogens that depend on or utilize this family of proteins. For 
example, Rab11 is key to the recycling endosome pathway in 
cells and plays a critical role in the assembly of multiple negative 
strand RNA viruses such as respiratory syncitial virus, Influenza 
A, and Sendai virus (113–115). Notably, the direct prenylation 
of pathogen proteins is also an important event in some bacte-
rial infections. For example, the PelH and AnkB proteins of 
Legionella pneumophila are known to require farnesylation, while 
SifA of Salmonella typhimurium requires geranylgeranylation for 
membrane association (116–118). The effects of 25-HC on these 
bacteria have yet to be characterized. Given the complexity of the 
Rab superfamily and the differential dependency of a range of 
pathogens on its functions, more work is required to determine 
whether 25-HC effects are mediated via this route.
An intriguing possibility is that microorganisms may exploit 
the disruption of Rab prenylation by 25-HC. Rab5a contributes to 
lysosomal degradation of L. monocytogenes in macrophages and 
a disruption of its geranylgeranylation in this context may prove 
advantageous to the bacterium. In this regard, data show that the 
growth of L. monocytogenes is greater in WT macrophages when 
compared to their CH25H−/− counterparts (100).
While several studies have identified an important role for 
25-HC in  vivo, questions remain regarding: where and when 
25-HC is synthesized after infection, how 25-HC synthesis is 
regulated in different anatomical locations, functional in  vivo 
intra- and extracellular concentrations, half-life in the tissues and 
circulation and therapeutic potential (84, 108). In 2014, Ikegami 
et al. analyzed oxysterol concentrations in serum of patients with 
chronic HCV infection and found 25-HC levels 44% greater than 
those in the controls. Notably, 25-HC levels decreased significantly 
in these HCV-infected patients after they had received PEGylated 
IFN and Ribavirin therapy for a period of 3 months (119).
The presence of INSIG homologs with potentially conserved 
25-HC-binding capacity in bacteria and yeast raises the intrigu-
ing possibility that the oxysterol can directly influence these 
organisms. An incomplete understanding of sterol metabolism in 
these organisms and, in some cases, an absence of SREBP, SCAP, 
or HMGCR homologs makes progress in this field challenging at 
present (96).
iFN-iNDUCeD miRNA RegULATiON OF 
STeROL MeTABOLiSM iN iNFeCTiON 
AND iMMUNiTY
miRNA are small (20–25 nt) RNA encoded in introns, exons, and 
intergenic regions of the mammalian genome and are typically 
co-expressed with a protein-coding or non-coding primary tran-
script. miRNA function to regulate gene expression via imperfect 
base-pairing to the 3′UTR of mRNA which results in the targeting 
of the transcript for degradation and/or an inhibition of transla-
tion. A key functional characteristic of miRNA is that they can 
target and regulate the expression of multiple transcripts in the 
cell. Since the discovery that miRNA, in particular miR-33, func-
tion to regulate cholesterol homeostasis, interest in this area has 
grown dramatically and more than 20 miRNAs are now known 
to directly target the sterol metabolic network [reviewed in Ref. 
(120)]. Notably, a small number of sterol-associated miRNA 
have been shown to be IFN regulated and a subset of these also 
contribute to the immune response to infection. Here, we will 
review what is known about these IFN-regulated sterol regula-
tory miRNA and discuss the mechanisms employed to inhibit 
pathogens.
STeROL PATHwAY TARgeTiNg BY miR-
342-5P geNeRATeS BROAD ANTiviRAL 
iMMUNiTY
miR-342 is encoded in an intron of the Ena-vasodilator-
stimulated phosphoprotein gene (EVL) in the mouse or Ena-
Vasp-Like (EVL) gene in the human and co-transcribed with this 
transcript. Transcription of miR-342 can be induced by all-trans 
retinoic acid or IFN and suppressed by CpG island methylation 
upstream of EVL. Processing of the primary transcript results in 
the production of a pre-miRNA hairpin encoding two functional 
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miRNA—miR-342-3p and miR-342-5p (7, 121–124). In vivo, 
the EVL transcript is primarily expressed in cells of the immune 
and nervous systems, however, a systematic tissue and cell-type 
analysis of miR-342 expression has yet to be undertaken (125). In 
macrophages, miR-342 has been identified as a PU.1-regulated 
miRNA contributing to myeloid differentiation and miR-342-5p 
shown to be a pro-inflammatory mediator capable of enhancing 
miR-155 expression (123, 124). miR-342-5p has recently been 
implicated in the regulation of SREBP1 and SREBP2 in a cancer 
cell line; however, biological roles and precise mechanisms for the 
miRNA in relation to sterol biosynthesis and the immune response 
were not addressed (126). In this regard, we recently demonstrated 
that, in BMDM, miR-342-5p is directly regulated by IFN via 
IRF1 (7). We further showed that miR-342-5p directly targets the 
master transcriptional regulator of the pathway SREBP2, multiple 
members of the sterol biosynthesis pathway including (IDI1 and 
SC4MOL) and can reduce miR-33 abundance in the cell (7). In 
doing so, miR-342-5p contributes to IFN-induced suppression of 
the sterol metabolic network—reducing the abundance of both 
sterol pathway metabolic intermediates and total cholesterol in 
macrophages. Notably, IFN-induced miR-342-5p suppression 
of the sterol metabolic network enables this miRNA to inhibit 
the replication of unrelated viruses including Influenza A and 
HSV1 (7). This study, in conjunction with our previous analysis 
of the antiviral effects 25-HC, highlights the complex, temporally 
coordinated, and redundant molecular circuitry utilized by the 
cell to regulate the sterol metabolic network during infection.
A summary of the molecular circuitry underlying the regu-
lation of sterol metabolism by IFN is presented in Figure 2. In 
murine BMDM, CH25H mRNA expression is regulated by STAT1 
and increases dramatically in the first half hour after activation 
of cells by IFN (52). In contrast, miR-342-5p expression increases 
from 2 to 3 h after IFN-γ activation of BMDM and is regulated 
by IRF1. Data from others and ourselves suggest, therefore, that a 
sequential IFN-elicited regulation of the sterol metabolic network 
exists in which 25-HC provides a rapid mechanism for decreasing 
sterol biosynthesis. It does this via an immediate proteosomal 
degradation of HMGCR and subsequent inhibition of SREBP2 
nuclear translocation. This leads to a suppression of viral entry 
and/or replication via an inhibition of sterol pathway flux—an 
outcome that will also activate STING to further stimulate type 
I IFN production. Since IFN-stimulated ATF3 swiftly inhibits 
CH25H transcription and 25-HC is rapidly catabolized, the 
CH25H response is primarily effective in limiting sterol synthesis 
for the first few hours of IFN induction. Importantly, however, 
miR-342-5p then further promotes a longer, sustained fine-tuning 
of sterol metabolism, and antiviral effects in the cell by targeting 
SREBF2 RNA and transcripts encoding select enzymes of the 
sterol biosynthesis pathway (e.g., IDI1 and SC4MOL). In this role, 
miR-342-5p complements and reinforces the antiviral functions 
of the rapidly induced oxysterol 25-HC on sterol biosynthesis.
While in  vitro data show that an inhibition of endogenous 
miR-342-5p can reduce the antiviral effects of exogenous IFN 
by 40–50%, the relative importance of this miRNA—and also 
25-HC—in  vivo are not known. A critical next step, therefore, 
will be the production of single miR-342-5p and combined miR-
342-5p/CH25H KO murine models in which the individual and 
combined functions of the miRNA and oxysterol can be tested in 
the context of infection.
miR-122 POSiTiveLY RegULATeS 
CHOLeSTeROL, FACiLiTATeS HCv 
RePLiCATiON, AND iS DOwNRegULATeD 
BY iFN
Arguably, the first miRNA associated with IFN responses to infec-
tion and the regulation of cholesterol metabolism was miR-122. 
miR-122 is a tissue-specific miRNA highly expressed in hepato-
cytes in which it constitutes around 70% of all miRNA present in 
the cell. In agreement with this strict tissue-specific expression, 
we failed to detect miR-122 in resting or IFN-activated bone 
marrow-derived macrophages (7). In 2005, Jopling et  al. (127) 
demonstrated a direct interaction between miR-122 and the 5′ 
region of the Hepatitis C genome and showed that this interaction 
results in the facilitation of viral replication (127). Subsequently, 
a role for miR-122 in the regulation of lipid metabolism was 
revealed when the administration of an antisense oligonucleotide 
(“antagomir”) to mice resulted in a significant reduction in circu-
lating cholesterol levels (128, 129). Further analyses of miR-122 
KO animals confirmed an absence of miR-122 results in reduced 
plasma cholesterol levels; however, it remains unclear what the 
specific sterol-related targets of miR-122 are and how this miRNA 
acts to regulate systemic cholesterol levels (130, 131). Notably, in 
2007, miR-122 was identified as an IFN-regulated miRNA whose 
abundance decreased by around 80% in Huh cells treated with 
IFNβ (132). Pedersen et al. further showed that the transfection 
of a miR-122 inhibitor into cells could suppress HCV replication 
with a similar magnitude of regulation to that induced by IFNβ 
alone (132). This and other findings have led to the development 
and in vivo testing of therapeutic miR-122 inhibitors that show 
promise for the treatment of chronic HCV infection (133, 134).
In summary, while miR-122 couples IFN to the regulation 
of sterol metabolism and, by direct interaction with the viral 
genome, plays a fundamental role in the replication of HCV, it 
is currently unknown whether the IFN suppression of miR-122 
directly influences circulating cholesterol levels and whether this 
plays a role in modulating host responses to infection.
miR-185 iS RegULATeD BY 25-HC AND 
iNHiBiTS viRUS RePLiCATiON BY 
TARgeTiNg LiPiD MeTABOLiSM
Recent evidence suggests that miR-185 functions to regulate 
sterol metabolism in the liver during an immune response to 
infection. In the absence of an infection or IFN treatment, data 
from hepatocytes show that miR-185 expression is downregu-
lated when cholesterol is depleted in  vitro and that expression 
of this miRNA is directly regulated by SREBP1c via a single 
sterol response element in its promoter (135). Multiple stud-
ies have further shown that this miRNA can regulate SR-BI, 
SREBP1c, SREBP2, HMGCR, and LDLR transcript abundance 
(126, 136, 137). Notably, in 2015, Li et al. showed that HCV can 
FigURe 2 | Mechanisms by which iFN can regulate the sterol metabolic network. See legend for glyph notation.
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upregulate SREBP2 via a core protein-mediated suppression 
of miR-185 (138) while Singaravelu et  al. demonstrated that 
miR-185 expression in hepatocytes is upregulated by 25-HC and 
restricts HCV replication via a repression of cellular lipid uptake 
and biosynthesis (111). Data suggest, therefore, that miR-185 
is antiviral, indirectly upregulated by IFN through 25-HC and 
exerts its effects (at least in hepatocytes) via a suppression of 
the sterol metabolic network. This mode of regulation was not 
detected in activated or infected murine macrophages and the 
general antiviral significance of these observations in alternative 
cell types has yet to be tested (7). Importantly, however, these data 
strongly support previous findings demonstrating a membrane-
independent antiviral mechanism for 25-HC.
miR-27 iNTegRATiON OF iMMUNiTY  
AND LiPiD MeTABOLiSM
Over the past decade, functional roles for miR-27 have been inves-
tigated in the context of several viral infections. In this regard, 
significant attention has focused on the ability of Herpesvirus 
saimiri and murine CMV to induce a reduction in miR-27 abun-
dance and the virus-related mechanisms mediating this reduc-
tion are now relatively well characterized (139–142). Notably, the 
functional consequences and benefit to the Herpesviruses of this 
reduction are incompletely understood with studies focusing on 
a suppression of miR-27-inducing constitutive T cell activation 
(Herpesvirus saimiri) or the suggestion that this event enhances 
IL-10 production during MCMV infection (142). Since 2013, 
several studies have described a miR-27 regulation of lipid 
(including sterol) metabolism. In 2013, Vickers et al. described 
a miR-27-mediated reduction in HMGCR abundance and a 
sensitivity of miR-27 to lipid levels in  vivo (143). Also at this 
time, Shirasaki et  al. described a HCV (but not IFN) induc-
tion of miR-27a in hepatocytes and a repression of ABCA1, 
SREBP1, and SREBP2 by the miRNA. They further showed 
that an inhibition of miR-27 increased cellular lipids/viral 
replication and an over-expression of the miRNA resulted in 
a reduction in viral infectivity and enhanced IFN signaling 
(144). In 2014, Singaravelu et  al. showed HCV induction of 
miR-27 is accompanied by the formation of large, abundant 
lipid droplets in hepatocytes. Zhang et al. further demonstrated 
this miRNA directly targets ABCA1, LPL, and ACAT1, and, in 
doing so, reduces cholesterol efflux/uptake and regulates the 
balance of free versus esterified cholesterol in THP1 cells (145). 
Notably, recent work from Zheng et  al. (146) describes a type 
1 IFN downregulation of miR-27 in macrophages resulting in 
enhanced SIGLEC1/TRIM27 expression. As a consequence, IFN 
signaling was suppressed and VSV replication enhanced (146). 
Taken together, the above studies suggest that miR-27 couples 
infection-induced IFN responses to the regulation of sterol 
metabolism. Importantly, however, the significance of miR-27 
and the relative importance of its sterol-regulatory effects in the 
context of specific infections and cell types are, incompletely 
understood. In this regard, we and others have demonstrated 
that MCMV is dependent on the sterol metabolic network for its 
replication. It may be hypothesized, therefore, that a suppression 
of miR-27 functions to upregulate the sterol metabolic network 
and, in doing so, enhances viral replication.
Alongside the examples discussed above, several other miR-
NAs hold promise as IFN-regulated modulators of the sterol 
metabolic network. Others, and ourselves, have demonstrated 
an IFN-elicited downregulation of miR-33 (7, 147). Recent work 
from Lai and colleagues demonstrates that miR-33 promotes pro-
inflammatory signaling via an ABCA1/ABCG1 augmentation of 
lipid raft microdomains (147). IFN-mediated downregulation 
of this miRNA, therefore, may serve to suppress the ongoing 
inflammatory response. Both viral infection and IFNγ can induce 
the expression of miR-19b—known to target ABCA1 (148, 149). 
Further, type 1 IFN (and hepatitis B virus) suppress the expres-
sion of miR-145—a miRNA known to target ABCA1 and HPV 
and play a role in the progression of atherosclerosis (150–154).
In summary, through their ability to simultaneously regulate 
multiple genes and propensity for fine-tuning rather than the 
induction of dramatic alterations in RNA expression, miRNA 
are ideally suited to the task of coordinating protective functions 
of the sterol metabolic network (on which the cell depends). 
Notably, work to-date supports cell- or tissue-specific expres-
sion of IFN-regulated miRNAs. In this regard, a great deal is 
still unknown about where and when IFN-regulated miRNA 
are expressed in vivo, how they are regulated by IFN and what 
their targets are in particular cell types in distinct species. In this 
regard, knockout miRNA models remain relatively scarce. There 
is a pressing need, therefore, for the development of new models 
to enhance our understanding of sterol regulatory miRNA and 
the roles they play in host protection against infection.
iSg RegULATiON OF THe STeROL 
MeTABOLiC NeTwORK DURiNg 
iNFeCTiON
While this review has focused on IFN-elicited oxysterol and 
miRNA-related mechanisms, several “conventional” ISG, integral 
to the cellular response to infection, also elicit their effects via the 
sterol metabolic network.
viPeRiN
Work characterizing the IFN-regulated gene Viperin (virus inhibi-
tory protein, endoplasmic reticulum-associated, IFN-inducible, 
or RSAD2) has demonstrated that this protein can inhibit both 
RNA and DNA viruses (155–158). Viperin can decrease HCMV 
late gene expression, block the release of Influenza A and HIV-1 
particles from the cell, and limit the replication of HCV, dengue 
virus, and WNV [reviewed in Ref. (159)]. Importantly, in vitro 
data show that Viperin inhibits Influenza A budding by disrupt-
ing cell membrane lipid raft integrity and increasing membrane 
fluidity. A key feature of this mechanism is the binding of Viperin 
to the sterol pathway enzyme farnesyl diphosphate synthase 
(FDPS)—an enzyme integral to sterol biosynthesis and the 
processes of farnesylation and geranylgeranylation (156,  158). 
Together, these observations suggest Viperin functions to 
inhibit Influenza A release via regulation of the sterol metabolic 
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network; however, a precise mechanism has yet to be determined. 
Unlike Influenza A and other viruses such as HIV-1 and Ebola, 
HCV does not bud from lipid rafts. HCV does, however, have 
an intimate relationship with cellular lipid metabolism—in 
particular, a dependency on lipid droplets. It has been suggested, 
therefore, that Viperin may inhibit HCV replication by alter-
ing the lipid composition of these droplets via its interaction 
with FDPS. This has not, however, been confirmed (160). Very 
recently, a TLR4/IRF3-dependent Viperin-induced reduction in 
membrane cholesterol and sphingomyelin was found to be key 
to the inhibition of Rabies virus replication in RAW264.7 cells 
(161). Taken together, the above studies highlight the importance 
of Viperin as a very early IFN-induced antiviral protein. While 
our mechanistic understanding is incomplete, it is notable that 
Viperin exerts at least some of its effects via the specific targeting 
of a key enzyme in the sterol metabolic network and a profound 
alteration of cellular membrane composition. Further work is 
required to confirm a conclusive link between these two obser-
vations and investigate mechanisms by which pathogens can 
exploit this protein for their own benefit (162).
iFiTM3
While the IFN-inducible transmembrane (IFITM) proteins 
were first described some 20 years ago, their antiviral properties 
remained unknown until 2009 when Brass et  al. demonstrated 
a functional role in cellular resistance to Influenza A, WNV, 
and Dengue virus (163). Since 2009, a plethora of studies have 
demonstrated the importance of IFITM proteins in suppressing 
virus-related morbidity and mortality and have characterized 
roles for the IFITM proteins in responses to a range of enveloped 
and non-enveloped viruses [reviewed in Ref. (164)]. Much of this 
work has focused on the ability of IFITM proteins to inhibit viral 
entry and/or the very early stages of viral replication. In this regard, 
in 2013, Amini-Bavil-Olyaee et  al. demonstrated that IFITM1, 
2, and 3 interact with vesicle-associated membrane protein A 
(VAPA) (165). VAPA is a highly conserved protein, generally 
found in the ER and, importantly, known to play a role in cho-
lesterol homeostasis via its interaction with OSBP. Under normal 
circumstances, OSBP is found in the cytoplasm where it serves 
as a cholesterol sensor and, together with VAPA, functions to 
redistribute cholesterol from the ER to other organelles in the cell. 
Amini-Bavil-Olyaee et al. (165) found that an IFITM-mediated 
disruption of the VAPA–OSBP interaction results in cholesterol 
levels increasing dramatically in late-endosomal compartments. 
They attributed a block in VSV release into the cytosol to this 
alteration in membrane composition (165). Notably, subsequent 
studies suggest an IFITM-mediated regulation of SNAREs and/
or regulation of protein lateral mobility may explain the ability of 
these proteins to inhibit IAV entry to the cell (166). Interestingly, 
Munoz-Moreno et al., very recently, described a role for IFITM2 
in protecting Vero cells against African Swine Fever Infection—a 
DNA virus (167). In agreement with previous work, they also 
described an IFITM-associated accumulation of cholesterol 
in cells, however, it remains unclear whether an IFN-induced 
IFITM-mediated regulation of the sterol metabolic network plays 
a direct role in the antiviral functions of this family of proteins.
CONCLUDiNg ReMARKS AND FUTURe 
PeRSPeCTiveS
Three decades after Cantell and colleagues speculated that IFN 
regulates sterol metabolism, the first evidence for a molecular 
coupling of IFN to the sterol metabolic network was provided 
by a systems biology investigation of macrophage responses to 
infection (4, 13). Given the wealth of clinical and molecular data 
now available, it is clear that an IFN-mediated reshaping of the 
sterol metabolic network is an integral, core component of the 
immune response to infection. The functional outcomes of this 
event are, however, only beginning to emerge for the wide array 
of immune-related cells and tissues in the body and are likely to 
be complex and context dependent. For example, in secondary 
lymphoid organs, 25-HC is indispensible as an intermedi-
ate metabolite crucial to B cell, T cell, and DC migration and 
antibody class switching. At a cell-intrinsic level, however, this 
oxysterol can also inhibit viral entry and replication. The latter 
occurs via the regulation of sterol biosynthesis through SREBP2 
and HMGCR in macrophages. A key question arising from work 
to-date is: how does the sterol metabolic network influence immu-
nity? Studies now show that the molecular coupling between IFN 
and sterol metabolism is bidirectional. In this regard, the recent 
work of York et  al. (33) is fascinating as it demonstrates the 
influence of sterol metabolic flux on antiviral IFN signaling (33). 
Similarly, Reboldi et  al. recently showed that the transcription 
factor SREBP2, whose function is tightly coupled to cholesterol 
homeostasis, functions to regulate inflammatory responses to 
infection and it has been demonstrated that a cholesterol loading 
of macrophages leads to a reduction in miR-342-5p abundance 
(33, 100, 168). In this context, relatively little is known about how 
the microbiome and diet, in particular, cholesterol intake, affect 
IFN responses to infection and this is an important question for 
the future.
Work to-date emphasizes the complexity of the molecular 
circuitry governing the regulation of sterol metabolism by IFN 
and vice  versa. Given IFN directly or indirectly regulates the 
expression of several hundred genes and the inherent complexity 
of the sterol metabolic network; it is likely that new bidirectional 
regulatory mechanisms will continue to appear. For example, 
we have shown that alongside the posttranscriptional and post-
translational effects of miR-342-5p and 25-HC, IFN can also 
repress SREBF2 transcription. The mechanism for this is unclear, 
however, epigenetic modifications may play a critical role and this 
will be important area to pursue in the future.
Given the many recent advances in our understanding of the 
role sterol metabolism plays in immunity to infection, how can 
we translate our new knowledge to clinical applications? While 
changes in systemic cholesterol levels may be of diagnostic 
value, the therapeutic targeting of host metabolic pathways for 
anti-infective treatment represents the most exciting application 
of our knowledge to-date. While statins are a widely utilized, 
clinically approved, therapy for regulating sterol metabolism 
and can inhibit a range of pathogens in vitro, in vivo utility in 
the context of infectious diseases remains inconclusive. The 
emergence of new pathogens and threat of antibiotic resistance 
means it is imperative that we develop new methods for treating 
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infectious diseases. While studies have explored oxysterol and 
miRNA inhibitor regulation of sterol metabolism in a preclinical 
and clinical context, legitimate concerns have been raised about 
the pharmacokinetics and potential side-effects of both. For 
example, the miR-122 inhibitor Miraversin can be effectively 
delivered in  vivo and substantially reduces HCV replication in 
a Chimpanzee model. Importantly, however, Miraversin admin-
istration is typically accompanied by an increase in circulating 
cholesterol leading to concerns that the cardiovascular health of 
recipients may be affected. Further, while miR-342-5p regulates 
sterol biosynthesis and, in doing so, can suppress viral replication 
it also targets AKT1 and, as a result, can promote inflammation 
(124). An important objective, therefore, will be to identify the 
specific mechanisms by which IFN-induced regulators of the 
sterol metabolic network function to suppress pathogen replica-
tion and specifically target these molecules. In doing so, undesired 
off-target effects will be reduced. In this context, several groups 
have already explored prenylation as a viable therapeutic target. 
Prenylation inhibitors are available as an oral medication and 
show promise in the treatment of, for example, HDV (169).
In conclusion, the sterol metabolic network has now moved 
center-stage in the context of IFN responses to infection and is 
increasingly recognized as a fundamentally important immune-
metabolomic system holding great promise in the next decades as 
target for diagnostic and therapeutic intervention.
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